


Analysis of UK medicines sales 2019

Branded medicines sales at net prices, £m

In 2019 under the VPAS and Statutory Scheme there were payments made totalling **£936 million**.

These payments are the result of payment percentages based on a forecast of growth, and any under/over delivery will be factored in future years' payments.



Growth 2019 vs 2018



Notes: VPAS and statutory scheme sales and income based on company returns (Q3 2020 data). Medicines sales at list prices based on Nov 2020 IQVIA data (BPI & HPAI); classes ATC K and T are excluded. Centrally procured vaccines list price sales included in the discount/ residual column (~£115m). Branded medicine sales at net price are subject to VPAS/SS payment.